- Home
- XELB vs SONN Comparison
XELB vs SONN Comparison
Compare XELB & SONN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XELB
- SONN
- Stock Information
- Founded
- XELB 2011
- SONN N/A
- Country
- XELB United States
- SONN United States
- Employees
- XELB N/A
- SONN N/A
- Industry
- XELB Multi-Sector Companies
- SONN Biotechnology: Pharmaceutical Preparations
- Sector
- XELB Miscellaneous
- SONN Health Care
- Exchange
- XELB Nasdaq
- SONN Nasdaq
- Market Cap
- XELB 3.7M
- SONN 3.8M
- IPO Year
- XELB N/A
- SONN N/A
- Fundamental
- Price
- XELB $1.31
- SONN $3.47
- Analyst Decision
- XELB
- SONN Strong Buy
- Analyst Count
- XELB 0
- SONN 1
- Target Price
- XELB N/A
- SONN $20.00
- AVG Volume (30 Days)
- XELB 1.4M
- SONN 726.3K
- Earning Date
- XELB 08-14-2025
- SONN 08-13-2025
- Dividend Yield
- XELB N/A
- SONN N/A
- EPS Growth
- XELB N/A
- SONN N/A
- EPS
- XELB N/A
- SONN N/A
- Revenue
- XELB $5,774,000.00
- SONN $1,000,000.00
- Revenue This Year
- XELB $23.96
- SONN $5,376.22
- Revenue Next Year
- XELB $53.02
- SONN N/A
- P/E Ratio
- XELB N/A
- SONN N/A
- Revenue Growth
- XELB N/A
- SONN 1689.52
- 52 Week Low
- XELB $0.95
- SONN $1.08
- 52 Week High
- XELB $8.49
- SONN $19.30
- Technical
- Relative Strength Index (RSI)
- XELB 49.93
- SONN 49.02
- Support Level
- XELB $1.13
- SONN $2.99
- Resistance Level
- XELB $1.20
- SONN $3.61
- Average True Range (ATR)
- XELB 0.11
- SONN 0.48
- MACD
- XELB 0.04
- SONN 0.01
- Stochastic Oscillator
- XELB 74.88
- SONN 54.70
About XELB Xcel Brands Inc.
Xcel Brands Inc is a media and brand management company. It is engaged in design, merchandising and planning, sourcing and production, licensing, marketing, and brand development. The company offers branded apparel, footwear, accessories, jewelry, home goods, and other consumer products. Its brand portfolio consists of the Isaac Mizrahi, Judith Ripka, H Halston, C Wonder, and the Highline Collective brands. The company licenses its brands to third parties, provides certain designs, production, and marketing services, and generates licensing, design, and service fee revenues through contractual arrangements and other agreements.
About SONN Sonnet BioTherapeutics Holdings Inc.
Sonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company. The Company views its operations and manages its business in one segment. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others.